Our Story
From breakthrough research to a global mission.
The Eyerising Journey
Founded by a World-Leading Researcher
Professor Mingguang He, a globally recognised ophthalmologist and researcher, identified the therapeutic potential of repeated low-level red-light therapy for slowing myopia progression in children. His clinical insight laid the scientific foundation for what would become Eyerising.
Early Research
Patented RLRL Technology
The team secured patents for the proprietary repeated low-level red-light device and treatment protocol, protecting a novel approach to non-invasive myopia management that had not existed anywhere in the world.
Patent Secured
First Clinical Trials Demonstrate Efficacy
Randomised controlled trials confirmed that RLRL therapy significantly reduces the rate of myopia progression in children, with results published in leading peer-reviewed ophthalmology journals. The clinical evidence base began to grow.
Clinical Trials
Eyerising China Launched
Eyerising launched in China, rapidly reaching over 80,000 patients through an extensive network of eye-care clinics. The scale of adoption validated the therapy's real-world effectiveness and safety profile.
China Launch
Eyerising International Established
Eyerising International was established in Melbourne, Australia, with the mission of bringing RLRL therapy to families worldwide. Co-founded by Professor Mingguang He and Jason Sun, the company built a team of ophthalmologists, clinical experts, and MedTech executives.
Melbourne, Australia
TGA Approval in Australia
The Eyerising device received TGA approval and was listed on the Australian Register of Therapeutic Goods (ARTG 412752), making it one of the first RLRL therapy devices approved by a stringent regulatory authority outside of China.
ARTG 412752
CE Marking for European Markets
Eyerising achieved CE marking, enabling access to European markets and further demonstrating the device's compliance with international medical device safety and performance standards.
CE Marking
Expanded to 30+ Countries Globally
Eyerising International now operates across more than 30 countries, with over 1,500 active patients receiving RLRL therapy through a growing network of clinician partners in the Asia-Pacific, Europe, the Middle East, and beyond.
Today
Looking Ahead
The myopia epidemic is accelerating. By 2050, an estimated 50% of the world's population is projected to be myopic. Eyerising International is committed to staying at the forefront of the scientific response to this global health challenge.
We are actively expanding our clinical trial programme across multiple countries, deepening our evidence base, and continuing to improve the Eyerising device and patient experience. New regulatory approvals are underway in key markets, and our distributor network continues to grow.
Our ambition is clear: to make effective, evidence-based myopia management accessible to every family that needs it, wherever they are in the world.
Be Part of the Story
Whether you are a clinician, researcher, distributor, or parent, there is a role for you in advancing myopia management worldwide.
Get in Touch